Brigitte Michelsen1,2, Eirik Klami Kristianslund1, Hilde Berner Hammer1, Karen Minde Fagerli1, Elisabeth Lie1, Ada Wierød3, Synøve Kalstad4, Erik Rødevand5, Frode Krøll6, Glenn Haugeberg7,8, Tore K Kvien1. 1. Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. 2. Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway. 3. Department of Rheumatology, Vestre Viken/Drammen Hospital, Drammen, Norway. 4. Department of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway. 5. Department of Rheumatology, St. Olavs Hospital, Trondheim, Norway. 6. Department of Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway. 7. Department of Rheumatology, Martina Hansens Hospital, Bærum, Norway. 8. Norwegian University of Science and Technology, Trondheim, Norway.
Abstract
OBJECTIVE: To investigate the predictive value of discordance between (1) tender and swollen joint count and (2) patient's and evaluator's global assessment on remission in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). METHODS: From the prospective, multicentre Norwegian-Disease-Modifying Antirheumatic Drug study, we included patients with RA and PsA starting first-time tumour necrosis factor inhibitors and DMARD-naïve patients starting methotrexate between 2000 and 2012. The predictive value of ΔTSJ (tender minus swollen joint counts) and ΔPEG (patient's minus evaluator's global assessment) on remission was explored in prespecified logistic regression models adjusted for age, sex, disease duration and smoking. RESULTS: A total of 2735 patients with RA and 1236 patients with PsA were included (mean (SD) age 55.0 (13.5)/48.3 (12.4) years, median(range) disease duration 0.7 (0.0-58.0)/1.3 (0.0-48.3) years, 69.7/48.4% females). Baseline ΔTSJ/ΔPEG reduced the likelihood of achieving DAS28<2.6, SDAI≤3.3, CDAI≤2.8, ACR/EULAR Boolean and DAPSA<4 remission after 3 and 6 months in RA (OR 0.95-0.97, p<0.001/OR 0.96-0.99, p≤0.01) and PsA (OR 0.91-0.94, p≤0.004/OR 0.89-0.99, p≤0.002), except for ΔPEG and 6-month DAS28 remission in PsA. CONCLUSIONS: Discordance between patient's and physician's evaluation of disease activity reflected through ΔTSJ and partly ΔPEG may reduce likelihood of remission in RA and PsA. The findings are relevant for use of the treat-to-target strategy in individual patients. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: To investigate the predictive value of discordance between (1) tender and swollen joint count and (2) patient's and evaluator's global assessment on remission in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). METHODS: From the prospective, multicentre Norwegian-Disease-Modifying Antirheumatic Drug study, we included patients with RA and PsA starting first-time tumour necrosis factor inhibitors and DMARD-naïve patients starting methotrexate between 2000 and 2012. The predictive value of ΔTSJ (tender minus swollen joint counts) and ΔPEG (patient's minus evaluator's global assessment) on remission was explored in prespecified logistic regression models adjusted for age, sex, disease duration and smoking. RESULTS: A total of 2735 patients with RA and 1236 patients with PsA were included (mean (SD) age 55.0 (13.5)/48.3 (12.4) years, median(range) disease duration 0.7 (0.0-58.0)/1.3 (0.0-48.3) years, 69.7/48.4% females). Baseline ΔTSJ/ΔPEG reduced the likelihood of achieving DAS28<2.6, SDAI≤3.3, CDAI≤2.8, ACR/EULAR Boolean and DAPSA<4 remission after 3 and 6 months in RA (OR 0.95-0.97, p<0.001/OR 0.96-0.99, p≤0.01) and PsA (OR 0.91-0.94, p≤0.004/OR 0.89-0.99, p≤0.002), except for ΔPEG and 6-month DAS28 remission in PsA. CONCLUSIONS: Discordance between patient's and physician's evaluation of disease activity reflected through ΔTSJ and partly ΔPEG may reduce likelihood of remission in RA and PsA. The findings are relevant for use of the treat-to-target strategy in individual patients. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Milena A Gianfrancesco; Laura Trupin; Stephen Shiboski; Mark van der Laan; Jonathan Graf; John Imboden; Jinoos Yazdany; Gabriela Schmajuk Journal: J Rheumatol Date: 2018-12-01 Impact factor: 4.666
Authors: Divya N Challa; Zoran Kvrgic; Andrea L Cheville; Cynthia S Crowson; Tim Bongartz; Thomas G Mason; Eric L Matteson; Clement J Michet; Scott T Persellin; Daniel E Schaffer; Theresa L Wampler Muskardin; Kerry Wright; John M Davis Journal: Arthritis Res Ther Date: 2017-09-26 Impact factor: 5.156
Authors: José Antonio Sacristán; Tatiana Dilla; Silvia Díaz-Cerezo; Clara Gabás-Rivera; Susana Aceituno; Luis Lizán Journal: PLoS One Date: 2020-06-17 Impact factor: 3.240